On Friday, Relmada Therapeutics Inc (NASDAQ: RLMD) opened higher 1.67% from the last session, before settling in for the closing price of $0.45. Price fluctuations for RLMD have ranged from $0.44 to $7.22 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 16.46% at the time writing. With a float of $25.17 million, this company’s outstanding shares have now reached $30.17 million.
Let’s look at the performance matrix of the company that is accounted for 20 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Relmada Therapeutics Inc (RLMD) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Relmada Therapeutics Inc is 16.58%, while institutional ownership is 41.26%. The most recent insider transaction that took place on Sep 11 ’24, was worth 153,707. In this transaction Chief Executive Officer of this company bought 51,407 shares at a rate of $2.99, taking the stock ownership to the 384,024 shares. Before that another transaction happened on Sep 09 ’24, when Company’s Chief Executive Officer bought 55,579 for $2.71, making the entire transaction worth $150,619. This insider now owns 299,603 shares in total.
Relmada Therapeutics Inc (RLMD) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.46% per share during the next fiscal year.
Relmada Therapeutics Inc (NASDAQ: RLMD) Trading Performance Indicators
Check out the current performance indicators for Relmada Therapeutics Inc (RLMD). In the past quarter, the stock posted a quick ratio of 6.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.87, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -1.15 in one year’s time.
Technical Analysis of Relmada Therapeutics Inc (RLMD)
Relmada Therapeutics Inc (NASDAQ: RLMD) saw its 5-day average volume 5.74 million, a positive change from its year-to-date volume of 0.3 million. As of the previous 9 days, the stock’s Stochastic %D was 0.49%. Additionally, its Average True Range was 0.36.
During the past 100 days, Relmada Therapeutics Inc’s (RLMD) raw stochastic average was set at 0.65%, which indicates a significant decrease from 0.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 608.84% in the past 14 days, which was higher than the 254.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.1260, while its 200-day Moving Average is $3.6216. Nevertheless, the first resistance level for the watch stands at $0.4855 in the near term. At $0.5134, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.5402. If the price goes on to break the first support level at $0.4308, it is likely to go to the next support level at $0.4040. The third support level lies at $0.3761 if the price breaches the second support level.
Relmada Therapeutics Inc (NASDAQ: RLMD) Key Stats
There are currently 30,174K shares outstanding in the company with a market cap of 14.03 million. Presently, the company’s annual sales total 0 K according to its annual income of -98,790 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -21,730 K.
